Loading…
Crop Life Science (CLSL)₹99.25−4.98%Pesticides & Agrochemicals
In the Mar 2026 quarter (consolidated), Crop Life Science reported sales of ₹86.74 Cr, down 7.5% from Mar 2025, and net profit of ₹4.01 Cr, up 33.2% year on year. For the year to Mar 2026, sales were ₹206 Cr and net profit ₹6.01 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2023 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 96.71 | 106 | 93.75 | 120 | 86.74 |
| Expenses | 90.88 | 97.93 | 86.01 | 112 | 77.01 |
| Operating Profit | 5.98 | 7.97 | 7.96 | 7.97 | 9.96 |
| OPM % | 7.0% | 8.0% | 9.0% | 7.0% | 11.0% |
| Other Income | 1.01 | 0.00 | 1.01 | 1.01 | 1.01 |
| Interest | 1.01 | 2.01 | 2.01 | 3.01 | 2.99 |
| Depreciation | 1.99 | 1.99 | 1.99 | 1.99 | 2.99 |
| Profit before tax | 4.01 | 4.01 | 4.01 | 4.01 | 5.01 |
| Tax % | 20.1% | 27.1% | 29.1% | 29.1% | 30.1% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.21 | −0.16 |
| Net Profit | 3.01 | 3.01 | 3.01 | 3.01 | 4.01 |
| EPS (Rs) | 1.97 | 1.84 | 1.62 | 1.80 | 2.10 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 130 | 191 | 195 | 206 |
| Expenses | 118 | 178 | 180 | 189 |
| Operating Profit | 11.95 | 12.94 | 15.93 | 17.93 |
| OPM % | 9.0% | 7.0% | 8.0% | 9.0% |
| Other Income | 1.01 | 2.01 | 1.01 | 2.01 |
| Interest | 3.01 | 3.01 | 5.01 | 4.99 |
| Depreciation | 3.99 | 2.99 | 4.98 | 4.99 |
| Profit before tax | 6.01 | 8.01 | 8.01 | 9.02 |
| Tax % | 27.1% | 26.1% | 28.1% | 30.1% |
| Exceptional items | 0.00 | 0.37 | −0.02 | 0.05 |
| Net Profit | 4.01 | 6.02 | 6.01 | 6.01 |
| EPS (Rs) | 3.40 | 3.52 | 3.45 | 3.88 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 12.03 | 17.03 | 17.04 | 17.04 |
| Reserves | 29.04 | 55.12 | 60.14 | 67.08 |
| Borrowings | 26.98 | 34.96 | 43.93 | 56.94 |
| Other Liabilities | 34.15 | 73.13 | 60.05 | 67.23 |
| Total Liabilities | 102 | 180 | 182 | 208 |
| Fixed Assets | 15.98 | 38.97 | 37.97 | 27.96 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.99 | 2.99 |
| Other Assets | 86.22 | 141 | 143 | 177 |
| Inventories | 25.97 | 39.96 | 48.92 | 70.89 |
| Trade receivables | 33.04 | 77.08 | 69.01 | 74.02 |
| Cash & equivalents | 0.00 | 2.01 | 1.01 | 3.01 |
| Total Assets | 102 | 180 | 182 | 208 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 1.99 | −7.98 | −1.99 | −7.98 |
| Cash from investing activity | −3.99 | −2.99 | −3.99 | 1.99 |
| Cash from financing activity | 0.99 | 12.96 | 3.99 | 21.94 |
| Net cash flow | −2.01 | 2.01 | −1.01 | 16.04 |
| Capex | 5.00 | 7.42 | 3.89 | 1.91 |
| Free cash flow | −2.99 | −12.95 | −5.98 | −3.99 |
| CFO / OP % | 34.0% | −49.0% | 0.0% | −28.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 91 | 147 | 128 | 130 |
| Inventory days | 104 | 99 | 126 | 170 |
| Days payable | 78 | 131 | 106 | 125 |
| Cash conversion cycle | 117 | 116 | 149 | 176 |
| Working capital days | 87 | 86 | 91 | 106 |
| ROCE % | — | 12.0% | 11.0% | 11.0% |
For the Mar 2026 quarter, Crop Life Science reported sales of ₹86.74 Cr, down 7.5% year on year and net profit of ₹4.01 Cr, up 33.2% year on year. The operating margin was 11.0%.
Crop Life Science's sales for the year to Mar 2026 were ₹206 Cr.
Net profit for the year to Mar 2026 was ₹6.01 Cr. Earnings per share over the same trailing period were ₹3.88.
Crop Life Science reported borrowings of ₹56.94 Cr at Mar 2026, against cash and equivalents of ₹3.01 Cr.
Cash from operations was −₹7.98 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹3.99 Cr.